News | Drug-Eluting Balloons | June 18, 2020

MedAlliance Sirolimus Drug Eluting Balloon Gains Second European CE Mark

MedAlliance announced its second CE mark approval for its Selution SLR 0.014 percutaneous transluminal coronary angioplasty (PTCA) sirolimus drug-eluting balloon (DEB) for the treatment of coronary artery disease. This includes indications for both de-novo lesions as well as in-stent restenosis. The approval applies to a broad range of balloon sizes, from 1.5 x 10 mm, up to 5 x 40 mm.

June 17, 2020 — MedAlliance announced its second CE mark approval for its Selution SLR 0.014 percutaneous transluminal coronary angioplasty (PTCA) sirolimus drug-eluting balloon (DEB) for the treatment of coronary artery disease. This includes indications for both de-novo lesions as well as in-stent restenosis. The approval applies to a broad range of balloon sizes, from 1.5 x 10 mm, up to 5 x 40 mm.

This European approval was supported by one-year results from the SELUTION SLR First-in-Human study, involving 56 patients enrolled across six centers in India, nearly half (46.6%) of whom had diabetes. 87.6% of patients had de-novo lesions and 12.4% had in-stent restenosis (ISR) lesions.

The primary endpoint of the study, freedom from device and procedure-related mortality through 30 days, was achieved in 100% of patients. There was no MACE (major adverse cardiovascular events) reported up to 30 days, and only one case occurring up to one year. Selution SLR demonstrated similar efficacy and safety to a drug-eluting stent (DES), with only a single patient requiring a TLR (target lesion revascularization). This single TLR case accounted for the low overall MACE rate of 2% at 12 months.

Co-Principal Investigators Dr. Shirish Hiremath, director of cath lab and consultant cardiologist, Ruby Hall Clinic, and Dr. Praveen Chandra, chairman, Department of Interventional Cardiology, Medanta - The Medicity, concluded that the data in this study support the safety, efficacy and optimal performance of Selution SLR in coronary applications.

"We are excited with the new technology in limus DEB Selution SLR," Hiremath said. DES has been the main stay of treating CAD for many years. But small vessel, long lesion, bifurcation and side branches, in-stent re-stenosis have been particularly challenging. With the limus DEB we can now offer alternative treatment modality and also "Leave Nothing Behind" to allow complete healing.

"I am extremely pleased with the CE mark approval of this innovative technology," added Dr. Chandra. "Small vessels and ISR are challenges for existing DES and DEB technologies, but this exciting new tool of a limus-eluting balloon can truly address the coronary conundrum of leaving nothing behind in the coronary artery, for complete healing." 

In February 2020 MedAlliance received CE mark approval for Selution SLR for the treatment of peripheral artery disease. The company recently announced completion of its below-the-knee (BTK) First-in-Human study in Singapore. The SAVE Study in Arterial Venus Fistula (AVF) enrolled its first patient in April. The STEP Pedal Arch study is to commence enrollment this quarter. A 500 patient post marketing clinical study will follow as well as the US IDE ISR study which will begin enrolment later this quarter.

MedAlliance is the first DEB company in the world to receive U.S. Food and Drug Administration (FDA) Breakthrough Device Designation Status for a coronary DEB. Selution SLR has now achieved this status for a range of indications: the treatment of AV-Fistula; coronary in-stent restenosis and peripheral below-the-knee lesions.

Selution SLR's technology involves unique MicroReservoirs made from biodegradable polymer intermixed with the anti-restenotic drug sirolimus. These MicroReservoirs provide controlled and sustained release of the drug. Extended release of sirolimus from stents has been proven highly efficacious in both coronary and peripheral vasculatures. MedAlliance's proprietary CAT (Cell Adherent Technology) enables the MicroReservoirs to be coated onto balloons and adhered to the vessel lumen when delivered via an angioplasty balloon.

For more information: medalliance.co

Related Content

Transit Scientific announced the U.S. Food and Drug Administration (FDA) cleared the XO Score Percutaneous Transluminal Angioplasty (PTA) Scoring Sheath platform for use in iliac, ilio-femoral, popliteal, infra-popliteal and renal arterial plus synthetic and/or native arteriovenous hemodialysis fistula. This is a new type of scoring balloon technology.
News | Balloon Catheter | June 04, 2020
June 4, 2020 — Transit Scientific announced the U.S.
NC Trek RX Coronary Dilatation Catheter is part of an FDA Class I recall because it may not defalte.
News | Balloon Catheter | February 24, 2020
February 24, 2020 — Abbott has voluntarily recalled specific lots of two types of its coronary angioplasty catheters
Edwards Lifesciences Recalls IntraClude Intra-aortic Occlusion Device
News | Balloon Catheter | July 15, 2019
Edwards LifeSciences is recalling the IntraClude Intra-Aortic Occlusion Device due to a risk of balloon rupture during...
Gore Molding & Occlusion Balloon for Endovascular Aortic Repair Receives FDA Approval
Technology | Balloon Catheter | August 23, 2018
W. L. Gore & Associates Inc. (Gore) announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the Gore...
Cardiovascular Systems Inc. and OrbusNeich Announce FDA Clearance  of Sapphire II Pro 1mm Coronary Balloon
Technology | Balloon Catheter | March 21, 2018
Cardiovascular Systems Inc. (CSI) recently announced that the U.S. Food and Drug Administration (FDA) has granted 510(k...
Cardiovascular Systems Expands Product Portfolio for Peripheral and Coronary Interventions
News | Balloon Catheter | January 24, 2018
Cardiovascular Systems Inc. recently announced two new partnerships broadening the company’s product portfolio. CSI is...
Abbott recalls its NC Balloon catheters
News | Balloon Catheter | May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports
Videos | Balloon Catheter | November 16, 2016
A discussion with Todd Brinton, M.D., about the newly FDA-cleared Shockwave Medical Lithoplasty System, at the Transc
NuCryo Vascular, Next Generation Cryoplasty Inflation Device, PolarCath Balloon Dilatation System

PolarCath Balloon Dilatation System image courtesy of NuCryo Vascular

Technology | Balloon Catheter | March 28, 2016
NuCryo Vascular LLC announced the launch of the Next Generation Cryoplasty Inflation device. The device received U.S....
NuCryo Vascular, FDA clearance, next-gen, PolarCath System, cryoplasty inflation device
Technology | Balloon Catheter | January 12, 2016
NuCryo Vascular LLC announced that they have received U.S. Food and Drug Administration (FDA) 510(k) clearance on the...